Phase 1 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People who have a confirmed diagnosis of ovarian cancer, specifically high-grade serous, high-grade endometrioid, low-grade serous, or clear cell ovarian cancer, or carcinosarcoma of the ovary (note: mucinous carcinoma of the ovary does not meet this criterion)
- People whose ovarian cancer has come back or stopped responding to treatment, and who have already received the standard treatments known to help — this includes cancer that has stopped responding to platinum-based chemotherapy, become resistant to it, or returned after it, provided there is clear documented medical reason why further platinum chemotherapy is not suitable
- People who are able to understand what the study involves and are willing to sign a written consent form agreeing to take part
- People of childbearing potential who are willing to use effective contraception throughout the study and for a set period of time after the last dose of the study treatment
Who may not be able to join:
- People who have another active cancer that could make it difficult to assess how well the study treatment is working
- People who have recently received another experimental drug or certain other cancer treatments within a specified period before the study would begin (confirm exact timeframes with trial site)
- People who are currently pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 510-392-0929
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of dose-limiting toxicities (DLTs) within the first cycle of treatment with NTB-928; Number of participants with adverse events (AEs) and serious adverse events (SAEs), by severity and relatedness to NTB-928; Maximum plasma concentration (Cmax); Time to Cmax (Tmax); Area under the plasma concentration-time curve (AUC) over the dosing interval (AUC0-T); AUC from time zero to time t (AUC0-t); AUC from time 0 extrapolated to infinity (AUC0-∞); Terminal elimination half-life (t½); Clearance (CL); Terminal elimination rate constant (λz); Volume of distribution (Vz); Accumulation ratio (Rac)...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.